Head to head
Metformin against Berberine
Berberine is sold as a natural alternative to metformin, and unusually for a supplement claim there is a direct trial behind the comparison. It is small, it is old and it was run in one country, all of which matters as much as the result.
Column A
MetforminMetformin hydrochloride (biguanide)
The most discussed drug in longevity, with enormous human safety data and a geroscience record that is consistently null. It also blunts the muscle and fitness gains from training.
Column B
BerberineBerberine hydrochloride
46 randomised trials show HbA1c down 0.73 percentage points, and a head to head against metformin found comparable glucose lowering. No outcome trial, mostly small single-region trials, and a third of patients get gastrointestinal side effects.
These two were tested against each other directly
A head to head trial, not two separate records compared by us.
In study A the authors report that the hypoglycaemic effect of berberine was similar to that of metformin. In the berberine group HbA1c fell from 9.5 to 7.5 percent, fasting glucose from 10.6 to 6.9 mmol/L and postprandial glucose from 19.8 to 11.1 mmol/L, all p below 0.01. Across the paper, 20 of 58 patients, 34.5 percent, had transient gastrointestinal adverse effects, and no liver or kidney damage was seen.
What the trial was
A pilot randomised trial. 36 adults with newly diagnosed type 2 diabetes were assigned to berberine or to metformin 0.5 g three times a day for three months. The paper also reports a separate single-arm study B in 48 adults with poorly controlled diabetes, which had no metformin comparator.
What the authors concluded
The authors conclude that berberine is a potent oral hypoglycaemic agent with beneficial effects on lipid metabolism, and describe study A as a pilot.
Where this result is weak
Eighteen people per arm for three months is a pilot, not a basis for substitution, and the paper says so. The metformin dose was 1.5 g a day, below the 2 g commonly used. There was no placebo arm, no blinding described, and the endpoints were glucose markers rather than any complication, hospitalisation or death. Metformin's evidence base includes outcome trials running for years; nothing comparable exists for berberine.
Side by side, on the facts we can check
| Attribute | Metformin | Berberine |
|---|---|---|
| Category | Longevity | Metabolic |
| FDA status | FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity. | Sold as a dietary supplement in the United States. Not approved for diabetes or any other indication. Used as a prescription antidiarrhoeal in some other countries. |
| Half-life | 4 to 9 hours (plasma), longer in erythrocytes | Systemically short with very low oral bioavailability, under 1%, which is why it is dosed two or three times a day with meals. Active metabolites including berberrubine circulate longer than the parent compound. |
| Molecular weight | 129.2 Da (165.6 Da as hydrochloride) | 336.4 Da as the free base, 371.8 Da as the hydrochloride. |
| Mechanism | Inhibits mitochondrial complex I and activates AMPK, reducing hepatic glucose output and improving insulin sensitivity. The AMPK account is incomplete and the relative contribution of complex I inhibition, mitochondrial glycerophosphate dehydrogenase and gut-mediated effects is actively disputed between research groups. | An isoquinoline alkaloid that activates AMP-activated protein kinase, which is the same node metformin acts through, largely via mild inhibition of mitochondrial complex I raising the AMP to ATP ratio. Downstream that increases glucose uptake, suppresses hepatic gluconeogenesis and reduces lipogenesis. It also upregulates LDL receptor expression by a route independent of statins, which explains the lipid effects, and alters gut microbiota composition. Oral bioavailability is very low, under 1%, so much of the effect is likely mediated in the gut and by metabolites rather than by systemic berberine. |
| Human studies cited | 3 | 1 |
| Legal status, US | Prescription only; approved for type 2 diabetes | Sold as a supplement |
Frequently asked questions
What is the difference between Metformin and Berberine?
Metformin: The most discussed drug in longevity, with enormous human safety data and a geroscience record that is consistently null. It also blunts the muscle and fitness gains from training. Berberine: 46 randomised trials show HbA1c down 0.73 percentage points, and a head to head against metformin found comparable glucose lowering. No outcome trial, mostly small single-region trials, and a third of patients get gastrointestinal side effects.
Which has stronger research evidence, Metformin or Berberine?
This database does not grade compounds. It counts what was run in people: 3 of the 4 studies cited on the Metformin profile were human work, against 1 of 3 for Berberine. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Metformin and Berberine FDA-approved?
Metformin: FDA approved for type 2 diabetes since 1994. Not approved for ageing or longevity.. Berberine: Sold as a dietary supplement in the United States. Not approved for diabetes or any other indication. Used as a prescription antidiarrhoeal in some other countries..
Related posts
Blog articles that cover Metformin or Berberine, newest first.
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.